CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

NCT ID: NCT06482684

Last Updated: 2024-07-01

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-15
• Study Completion Date: 2031-12-31

Brief Summary

First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.

Detailed Description

This phase II clinical trial will compare the efficacy, safety and tolerability of first-line treatment with KTE-X19 after a shortened induction with Rituximab and Ibrutinib to conventional immunochemotherapy and Ibrutinib followed by ASCT in younger patients in high-risk MCL patients or immunochemotherapy plus BTKi for elderly, but still fit patients (need to be CAR-T-cell eligible). As primarily the potential of CAR-T-cell treatment is evaluated within this trial, in case of failure to achieve a partial response will be treated with 2 additional cycles of R-CHOP, which can be omitted in case of sufficient response to Ibrutinib-based treatment.

Conditions

Mantle Cell Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

The abbreviated induction phase consists of 2 cycles of Ibrutinib + Rituximab and 2 cycles of Ibrutinib + R-CHOP for primary tumor reduction followed by CAR-T-cell treatment. In case of good clinical response (PR or CR) after 2 cycles of Ibrutinib + Rituximab, Ibrutinib + R-CHOP can be omitted. In this case, one cycle of Ibrutinib monotherapy will be applied. T cell apheresis will be performed after the initial 2 cycles. Application of KTE-X19 will be performed after lymphodepleting chemotherapy with Fludarabine and Cyclophosphamide (FC). After stable hematopoietic recovery, maintenance with Ibrutinib will be applied for 6 months but not prior to day 60 post CAR. The follow-up period starts after the completion of Ibrutinib maintenance and takes 4.5 up to 7 years.

Group Type: EXPERIMENTAL

KTE-X19

Intervention Type: DRUG

See description of treatment arms

Ibrutinib

Intervention Type: DRUG

See description of treatment arms

Arm B

Younger patients (≤ 65 years) will receive 3 cycles R-CHOP + Ibrutinib/ 3 cycles R-DHAP alternating, followed by autologous stem cell transplantation (ASCT). Elderly patients (≥ 65 years) will receive 6 cycles of Bendamustine and Rituximab + Ibrutinib or R-CHOP + Ibrutinib without ASCT. Independently of age, control patients receive 2 years of maintenance therapy with Ibrutinib and 3 years of Rituximab maintenance if foreseen by national guidelines, in addition to Ibrutinib maintenance.

Group Type: ACTIVE_COMPARATOR

Ibrutinib

Intervention Type: DRUG

See description of treatment arms

Interventions

KTE-X19

See description of treatment arms

Intervention Type: DRUG

Ibrutinib

See description of treatment arms

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed diagnosis of MCL according to WHO classification, with documentation of either overexpression of cyclin D1 or presence of t(11;14)

2. At least one High Risk MCL - feature as defined as I. MIPI-c high intermediate (HI) or high (H) risk (i.e. high risk MIPI irrespective of Ki-67 or intermediate risk MIPI and Ki-67>=30% (Ki-67 based on local pathology) and/or II. TP53-mutation and/or TP53-overexpression by immunohistochemistry (> 50% of lymphoma cells)

3. No prior treatment for MCL

4. Stage II-IV (Ann Arbor)

5. 18-75 years

6. At least 1 measurable lesion according to the Lugano Response Criteria (>1.5 cm nodal lesion or > 1cm extranodal lesion); in case of bone marrow infiltration only, bone marrow aspiration and biopsy is mandatory for all staging evaluations.

7. ECOG performance status ≤ 2

8. The following laboratory values at screening (unless discrepancies are related to MCL):

I. Absolute neutrophil count (ANC) ≥ 1000 cells/μL II. Platelets ≥75,000 cells/μL III. Creatinine <2 mg/dL or calculated creatinine clearance ≥60 mL/min IV. Transaminases (AST and ALT) < 2.5 x ULN V. Total bilirubin <= 2 x ULN unless other reason known (e.g. Gilbert-Meulengracht-Syndrome, or due to lymphoma involvement)

9. No evidence of CNS-disease

10. Written informed consent form according to ICH/EU GCP and national regulations, ability to follow study instructions and likely to attend and complete all required visits

11. Sexually active men and women of child-bearing potential must agree to use one of the highly effective contraceptive methods (combined oral contraceptives using two hormones, contraceptive implants, injectables, intrauterine devices, sterilized partner) together with one of the barrier methods (latex condoms, diaphragms, contraceptive caps) while on study; this should be maintained for 6 months after the last dose of KTE-X19 or for 3 months after last dose of Ibrutinib, whichever is longer

12. Negative serum or urine pregnancy test (Females of childbearing potential only, Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)

13. Willingness not to drive a motor vehicle for 8 weeks post CAR T cell treatment

14. Possibility to reach the site within 2 hours in case of toxicity / emergency

Exclusion Criteria

1. Subjects not able to give consent

2. Subjects without legal capacity, unable to understand the nature, scope, significance and consequences of this clinical study

3. Known history of hypersensitivity to the investigational drug, to drugs with a similar chemical structure or to aminoglycosides

4. Simultaneously active participation in another clinical study involving an investigational medicinal product within 30 days prior to enrollment. Patients included in follow up periods of other clinical trials without ongoing trial medication are allowed

5. Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the study results, or may interfere with the subject's participation in this clinical study

6. Known or persistent abuse of medication, drugs or alcohol

7. Serious concomitant disease interfering with a regular therapy according to the study protocol:

I. Clinically significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, higher grade AV-block, unstable angina, myocardial infarction, cardiac angioplasty or stenting within 12 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below 50% II. Baseline oxygen saturation ≤ 92% on room air III. Clinical significant pleural effusion (if not lymphoma related) IV. Endocrinological (severe, not sufficiently controlled diabetes mellitus)

8. Current or planned pregnancy or nursing women. History of or active malignancy other than MCL, non-melanoma skin cancer, carcinoma in situ (e.g. cervix, bladder, breast) or prostate cancer unless disease-free for at least 3 years (and PSA within normal range in case of prostate cancer).

9. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management.

10. Positive test results for chronic HBV infection (defined as positive HBsAg serology) (mandatory testing) Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable

11. Positive test results for hepatitis C (mandatory hepatitis C virus [HCV] antibody serology testing). Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA

12. Patients with known HIV infection (mandatory test)

13. History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or any autoimmune disease with CNS involvement

14. History of or active autoimmune disease (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression / systemic medication within the last 2 years

15. History of deep vein thrombosis or pulmonary embolism requiring therapeutic anticoagulation within 6 months of enrolment

16. Known severe primary immunodeficiency

17. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment

18. Live vaccine ≤ 6 weeks prior to planned start of study treatment

19. Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow up schedule

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Johannes Gutenberg University Mainz

OTHER

Sponsor Role: collaborator

Christian Schmidt, MD

OTHER

Sponsor Role: lead

Responsible Party

Christian Schmidt, MD

Head of Study Center

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Georg Hess, MD

Role: PRINCIPAL_INVESTIGATOR

Johannes Gutenberg University Mainz

Locations

University Hospital of Mainz

Mainz, , Germany

Site Status: RECRUITING

Klinikum der Universität München

Munich, , Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Martin Dreyling, MD

Role: CONTACT

Martin.Dreyling@med.uni-muenchen.de

+4989440074900

Christian Schmidt, MD

Role: CONTACT

christian_schmidt@med.uni-muenchen.de

+4989440077907

Facility Contacts

Georg Hess, MD

Role: primary

georg.hess@unimedizin-mainz.de

+49 6131 175040

Christian Schmidt, MD

Role: primary

+49 (0)89 4400-77907

Christian Schmidt, MD

Role: backup

Christian_Schmidt@med.uni-muenchen.de

+49 (0)89 4400-77907

References

Silkenstedt E, Dreyling M. First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients. Hematol Oncol. 2025 Jun;43 Suppl 2(Suppl 2):e70073. doi: 10.1002/hon.70073.

Reference Type: DERIVED

PMID: 40517546 (View on PubMed)

Other Identifiers

2022-502405-15-01

Identifier Type: CTIS

Identifier Source: secondary_id

CARMAN

Identifier Type: -

Identifier Source: org_study_id